Deals this week: Myovant Sciences, Biogen, Telix Pharmaceuticals

20th October 2017 (Last Updated October 20th, 2017 09:44)

Myovant Sciences Ltd plans to raise $60m through the private placement of 15% notes bearing a maturity date of 16 October 2023.

Myovant Sciences Ltd plans to raise $60m through the private placement of 15% notes bearing a maturity date of 16 October 2023.

The UK-based biopharmaceutical company plans to use the proceeds towards Phase III trials of its relugolix compound.

Biogen Inc. and Genomics Plc have formed a partnership to develop treatments for multiple sclerosis.

Biogen is a biotechnology company based in the US, while Genomics is an algorithms and software solutions developer based in the UK.

"Biogen Inc. and Genomics Plc have formed a partnership to develop treatments for multiple sclerosis."

Telix Pharmaceuticals Limited plans to raise A$50.05m ($39.46m) through an initial public offering (IPO) of 77 million shares of its common stock priced at A$0.65 ($0.51) a share.

The Australian clinical-stage biotechnology company plans to use the funds to accomplish major product development milestones.

US-based biopharmaceutical company Albireo Pharma, Inc. plans to raise $125m through the issue of common stock or preferred stock, preferred stock or debt securities or any combination of securities.

The company plans to use the funds to advance the development of its A4250 and A3384 product candidates.

German biopharmaceutical company InflaRx GmbH has secured $55m in a series D funding round led by Bain Capital Life Sciences LP.

The company plans to use the funds to carry out clinical Phase IIb trials on its IFX-1 drug candidate, which is indicated for the treatment of chronic inflammatory and auto-immune diseases.